Hedgehog signaling pathway

From WikiMD's Medical Encyclopedia

Revision as of 22:01, 28 February 2024 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Hedgehog signaling pathway is a key cell signaling system that plays a crucial role in the development of organisms across the animal kingdom. It is named after the Hedgehog (Hh) gene, which was first identified in the fruit fly species Drosophila melanogaster. The pathway is involved in the regulation of cell growth, cell differentiation, and the formation of the body plan.

Function

The Hedgehog signaling pathway is activated when a Hedgehog protein binds to the Patched (Ptc) receptor on the cell surface. In the absence of Hedgehog, Patched inhibits another protein called Smoothened (Smo). When Hedgehog binds to Patched, this inhibition is relieved, allowing Smoothened to activate a series of downstream signaling events. These events ultimately lead to the activation of Gli transcription factors, which regulate the expression of target genes.

Role in Development

During embryonic development, the Hedgehog signaling pathway helps to establish the body plan. It does this by determining the pattern of tissue growth and the differentiation of cells into different types. For example, in the developing vertebrate limb, Hedgehog signaling is involved in determining the pattern of digit formation.

Role in Disease

Abnormalities in the Hedgehog signaling pathway can lead to a variety of diseases. Overactivation of the pathway can lead to cancer, including basal cell carcinoma, the most common type of skin cancer, and medulloblastoma, a type of brain cancer. Mutations in components of the pathway can also cause congenital disorders, such as Holoprosencephaly, a severe brain malformation, and Gorlin syndrome, a condition characterized by the development of multiple basal cell carcinomas and other abnormalities.

Therapeutic Target

Given its role in disease, the Hedgehog signaling pathway is a target for therapeutic intervention. Several drugs that inhibit the pathway are currently in clinical use or under development. These include vismodegib and sonidegib, which are used to treat basal cell carcinoma.

See Also


This cell biology related article is a stub. You can help WikiMD by expanding it.


Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!



Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.